AIML Subsidiary NeuralCloud Enters Research Services Agreement with Baker Heart and Diabetes Institute to Support AI-Driven ECG Analysis

Agreement expands NeuralCloud's role in cardiovascular research and academic collaborations MaxYield™ platform to support heart rate variability analysis in post-exertional malaise research TORONTO, ON / ACCESS Newswire / March 25, 2026 / NeuralCloud Solutions Inc. ("NeuralCloud"), a subsidiary of AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB), is pleased to announce that on March 18th, 2026 the Company entered into a research services agreement with Dr. Kegan Moneghetti, MBBS (Hons) FRACP FCSANZ PhD, of the Baker Heart and Diabetes Institute, to provide AI-powered ECG signal processing in support of an ongoing cardiovascular research study. Under the agreement, NeuralCloud will apply its proprietary MaxYield™ ECG processing platform to existing ECG recordings supplied by the research team.